Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral pipeline with a Phase III drug designed to prevent influenza in individuals at higher risk of complications.
That Phase III drug—Cidara’s lead pipeline candidate CD388—is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza. CD388 consists of a small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody designed to prevent influenza A and B.
CD388 is now under study in the Phase III ANCHOR trial (NCT07159763), which is assessing the drug among adult and adolescent participants deemed to be at higher risk of developing complications from influenza.
“We intend to…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
